Cargando…

Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone

Background. Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be combined to increase efficacy. Objective. We used MTX, RTX, and methylprednisolone in a single combined regiment and observed patients prospectively. Methods. We present resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Evdoshenko, Evgeniy, Maslyanskiy, Alexey, Lapin, Sergey, Zaslavsky, Leonid, Dobson, Ruth, Totolian, Areg, Skoromets, Alexander, Bar-Or, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784158/
https://www.ncbi.nlm.nih.gov/pubmed/24109519
http://dx.doi.org/10.1155/2013/748127
_version_ 1782477527672946688
author Evdoshenko, Evgeniy
Maslyanskiy, Alexey
Lapin, Sergey
Zaslavsky, Leonid
Dobson, Ruth
Totolian, Areg
Skoromets, Alexander
Bar-Or, Amit
author_facet Evdoshenko, Evgeniy
Maslyanskiy, Alexey
Lapin, Sergey
Zaslavsky, Leonid
Dobson, Ruth
Totolian, Areg
Skoromets, Alexander
Bar-Or, Amit
author_sort Evdoshenko, Evgeniy
collection PubMed
description Background. Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be combined to increase efficacy. Objective. We used MTX, RTX, and methylprednisolone in a single combined regiment and observed patients prospectively. Methods. We present results of observational pilot study of combined therapy of RTX and MTX in 28 patients with active MS. Therapeutic protocol consisted of two infusions within 14 days. First infusion was 1000 mg methylprednisolone (MP) IV, 1000 mg RTX IV, and 20 mg MTX IV. On day 14, 1000 mg MP IV and 1000 mg RTX IV were given. Patients were followed prospectively from 12 to 48 months. Results and Conclusion. There were no relapses among all 28 patients during the observation period. B-cell depletion of CD19+ and CD19+/CD27+ memory B-cell subpopulation in both compartments was confirmed in all patients at 6 months. We found a more rapid reconstitution of B cells in the CSF than in the peripheral blood and longstanding depression of CD19+CD27+ memory B-cell. Conclusion. Effectiveness of combined regimen of RTX and MTX could be related to longstanding depletion of CD19+CD27+ memory B-cell subset.
format Online
Article
Text
id pubmed-3784158
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37841582013-10-09 Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone Evdoshenko, Evgeniy Maslyanskiy, Alexey Lapin, Sergey Zaslavsky, Leonid Dobson, Ruth Totolian, Areg Skoromets, Alexander Bar-Or, Amit ISRN Neurol Clinical Study Background. Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be combined to increase efficacy. Objective. We used MTX, RTX, and methylprednisolone in a single combined regiment and observed patients prospectively. Methods. We present results of observational pilot study of combined therapy of RTX and MTX in 28 patients with active MS. Therapeutic protocol consisted of two infusions within 14 days. First infusion was 1000 mg methylprednisolone (MP) IV, 1000 mg RTX IV, and 20 mg MTX IV. On day 14, 1000 mg MP IV and 1000 mg RTX IV were given. Patients were followed prospectively from 12 to 48 months. Results and Conclusion. There were no relapses among all 28 patients during the observation period. B-cell depletion of CD19+ and CD19+/CD27+ memory B-cell subpopulation in both compartments was confirmed in all patients at 6 months. We found a more rapid reconstitution of B cells in the CSF than in the peripheral blood and longstanding depression of CD19+CD27+ memory B-cell. Conclusion. Effectiveness of combined regimen of RTX and MTX could be related to longstanding depletion of CD19+CD27+ memory B-cell subset. Hindawi Publishing Corporation 2013-09-10 /pmc/articles/PMC3784158/ /pubmed/24109519 http://dx.doi.org/10.1155/2013/748127 Text en Copyright © 2013 Evgeniy Evdoshenko et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Evdoshenko, Evgeniy
Maslyanskiy, Alexey
Lapin, Sergey
Zaslavsky, Leonid
Dobson, Ruth
Totolian, Areg
Skoromets, Alexander
Bar-Or, Amit
Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone
title Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone
title_full Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone
title_fullStr Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone
title_full_unstemmed Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone
title_short Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone
title_sort dynamics of b-cell populations in csf and blood in patients treated with a combination of rituximab and mitoxantrone
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784158/
https://www.ncbi.nlm.nih.gov/pubmed/24109519
http://dx.doi.org/10.1155/2013/748127
work_keys_str_mv AT evdoshenkoevgeniy dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone
AT maslyanskiyalexey dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone
AT lapinsergey dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone
AT zaslavskyleonid dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone
AT dobsonruth dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone
AT totolianareg dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone
AT skorometsalexander dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone
AT baroramit dynamicsofbcellpopulationsincsfandbloodinpatientstreatedwithacombinationofrituximabandmitoxantrone